Cargando…
Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies
The Covid-19 disease has recently become one of the biggest challenges globally, and there is still no specific medication. Findings showed the immune system in severe Covid-19 patients loses regulatory control of pro-inflammatory cytokines, especially IL-6 production, called the “Cytokine storm” pr...
Autores principales: | Kaffash Farkhad, Najmeh, Reihani, Hamidreza, sedaghat, Alireza, Moghadam, Amir Adhami, Moghadam, Ahmad Bagheri, Tavakol-Afshari, Jalil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185247/ https://www.ncbi.nlm.nih.gov/pubmed/34124322 http://dx.doi.org/10.1016/j.reth.2021.05.007 |
Ejemplares similares
-
Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
por: Kaffash Farkhad, Najmeh, et al.
Publicado: (2022) -
Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis
por: Tavakol-Afshari, Jalil, et al.
Publicado: (2021) -
Chromosomal Instability in Various Generations of Human Mesenchymal Stem Cells Following the Therapeutic Radiation
por: Sadeghi Moghadam, Majid, et al.
Publicado: (2023) -
Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review of disease information and future perspectives
por: Najafi, Shahrzad, et al.
Publicado: (2023) -
Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms
por: Kaffash Farkhad, Najmeh, et al.
Publicado: (2022)